Tag: atherosclerotic cardiovascular disease

illustration showing action of a GLP-1 receptor agonist
November 20, 2023/Preventive Cardiology

Semaglutide Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes

Findings establish overweight/obesity as a modifiable risk factor for cardiovascular disease

22-HVI-3411464_GLP-1-and-GIP-dual-agonism_650x450
December 19, 2022/Preventive Cardiology

New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight

Two major trials promise key progress against the last unaddressed major risk factor

BackPage 1 of 1Next
Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Ad